MedTrace Logo

Continuous Infusion of Linezolid Versus Intermittent Dosing in the Treatment of Nosocomial Pneumonia

NCT04531332 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 169

Last updated 2021-09-16

No results posted yet for this study

Summary

The investigator's goal in this study is to determine the clinical efficacy and safety of continuous infusion in comparison with standard intermittent infusion.

Conditions

Interventions

DRUG

Continuous infusion Linezolid

Linezolid 600 mg intravenous Loading dose followed by 1200 mg/ day by Continuous infusion ( 50 mg /hr )

DRUG

intermittent dosing linezolid

Linezolid 600 mg intravenous twice daily

Sponsors & Collaborators

  • Beni-Suef University

    collaborator OTHER

  • October 6 University

    lead OTHER

Principal Investigators

  • Ahmed Essam, BSc · October 6 University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-15
Primary Completion
2021-09-15
Completion
2021-09-15

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04531332 on ClinicalTrials.gov